Key Highlights
● AFL closed at $114.48 on 9 October 2026, and the $115.77 consensus target implies upside of only about 1.1%.
● The consensus draws on 14 ratings, with targets from $101 to $138, while the second data set shows a $118.53 mean from 15 analysts.
● Market data shows four Buy, seven Hold and three Sell ratings, and both data sets rate the stock Hold overall.
● Keefe, Bruyette & Woods cut its target to $120 from $125 on 9 October, and Mizuho cut to $107 from $116 on 7 October.
Aflac Incorporated (NYSE:AFL), the supplemental health and life insurer, is a constituent of the S&P 500. The shares closed at $114.48 on Friday 9 October 2026, only slightly below the consensus analyst target.
What Is the Latest Analyst Price Target?
Market data reports a consensus price target of $115.77 from 14 ratings in the past twelve months, with a high of $138.00 and a low of $101.00. Against the $114.48 close, the consensus suggests upside of only about 1.1%. The second data set, based on third-party data from 15 analysts, shows a mean of $118.53, a median of $116 and a range of $99 to $138, with its page dated 2 October 2026, when it quoted a price of $111.54, so it may not reflect the latest broker changes. Both data sets rate the stock Hold overall.
The market data figure is consistent with the recent named broker targets, which cluster between $101 and $125.
What Are Wall Street Analysts Saying?
Market data records four Buy ratings (including two Strong Buy), seven Hold and three Sell. Opinion is therefore split, with a modest bearish tilt among recent actions. According to market data, Keefe, Bruyette & Woods lowered its target from $125 to $120 on 9 October, keeping a Market Perform rating. Barclays reiterated Underweight on 7 October with a target of $101, up from $99, and Mizuho lowered its Underperform target from $116 to $107 the same day. UBS reiterated Neutral on 6 October, lifting its target from $124 to $125.
Earlier, Wells Fargo set a $122 target at Equal Weight on 19 August, and Wolfe Research initiated at Underperform with a $103 target. JPMorgan trimmed its Neutral target to $116 on 11 August, while Piper Sandler reiterated Overweight and raised its target from $130 to $138 on 10 August.
What Could Help the Stock Reach the Price Target?
With the consensus only slightly above the share price, the stock is already trading close to what analysts collectively see as fair value, so the bullish case rests mainly on estimates being exceeded. Stable underwriting results, steady premium and persistency trends, and continued capital returns would support that view. Market data cites a dividend yield of about 2.2%, although it gives no per-share detail.
What Could Prevent the Stock Reaching the Target?
The bearish end of the range is substantial: Barclays at $101, Wolfe Research at $103 and Mizuho at $107 all sit below the current price. Market data reports revenue down 1.0% year on year in the latest quarter and earnings per share of $1.75 against a $1.76 consensus. Currency movements between the yen and the dollar, changes in interest rates, claims experience and regulatory shifts could also affect results. Recent target cuts from Keefe, Bruyette & Woods and Mizuho suggest some analysts are lowering expectations.
What Should Investors Watch Next?
Items to watch include further broker target revisions, the yen-dollar exchange rate, interest-rate moves and any updates to the company's capital return plans.
Aflac's Narrow Target Gap Meets a Split Panel
Aflac closed at $114.48 on 9 October 2026, within about 1.1% of the $115.77 consensus target, so the bullish case rests mainly on estimates being exceeded. Opinion is split, with four Buy, seven Hold and three Sell ratings, and Barclays at $101, Wolfe Research at $103 and Mizuho at $107 all sit below the current price, while Piper Sandler holds the top target at $138. Market data cites a dividend yield of about 2.2%, while the latest quarter showed revenue down 1.0% year on year and earnings per share of $1.75 against a $1.76 consensus.






Please wait processing your request...